Kamada (KMDA) Scheduled to Post Earnings on Wednesday

Kamada (NASDAQ:KMDA) will be releasing its earnings data before the market opens on Wednesday, November 13th. Analysts expect Kamada to post earnings of $0.07 per share for the quarter. Kamada has set its FY 2024 guidance at EPS.

Kamada (NASDAQ:KMDA) last released its earnings results on Wednesday, August 14th. The biotechnology company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. Kamada had a return on equity of 6.15% and a net margin of 9.75%. The company had revenue of $42.47 million during the quarter, compared to analysts’ expectations of $39.70 million. On average, analysts expect Kamada to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kamada Price Performance

Shares of NASDAQ:KMDA opened at $5.99 on Thursday. Kamada has a fifty-two week low of $4.58 and a fifty-two week high of $6.53. The firm has a 50-day simple moving average of $5.42 and a 200 day simple moving average of $5.43. The company has a market cap of $344.31 million, a PE ratio of 22.19 and a beta of 1.05.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Kamada in a report on Thursday, August 15th. StockNews.com lowered Kamada from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 27th.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.